Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register

Background: Sulfonylureas (SU) are often used for second and third line type 2 diabetes mellitus (T2DM) therapy. Currently, there are no unified recommendations governing the choice of drugs for the second line therapy. This requires clarification.Aim: To examine Moscow Region DM register data for assessing ongoing antihyperglycemic therapy and its correspondence to current local and international T2DM treatment recommendations, as well as actual clinical recommendations for the treatment of T2DM patients and COVID-19.Materials and methods: The structure of glucose-lowering therapy with non-insulin drugs (NID) was studied in T2DM patients according to the data T2DM register of Moscow region. The analysis was carried out on 06.02.2021. We analyzed the general group of T2DM patients (237479 people), group 60 years and older (188644 patients), T2DM patients who have had COVID-19. Newly diagnosed T2DM individuals were analyzed for 2020 (5088 people).Results: Glucose-lowering therapy is received by 97.6% of T2DM patients. Of these, 79.07% take NID, insulin + NID - 11.37%. Monotherapy is received by 44.4% of patients, a combination of two drugs - 29.3%, out of three - 5.3% of patients. Metformin is the leader in prescribing NID (69.4% of all T2DM patients and 81.3% in newly diagnosed patients). SU are in second place in T2DM treatment (50% of all patients, 24.1% in newly diagnosed patients), iIDPP-4 is in third place (12.1% and 12.6%, respectively). Among patients of 60 and more years old, 25.99% of patients take gliclazide MR, 14.3% glibenclamide, 7.7% glimepiride. Mortality from COVID-19 depends on the diabetes duration.Conclusion: According to the DM register, half of the T2DM patients and a quarter of T2DM newly diagnosed patients get SU. As a first-line drug, SU is on the second place after metformin and are most often used in double and triple combinations of T2DM therapy. In the older age group on SU, preference is given to gliclazide MR

Prevalence of diabetes mellitus in patients with acromegaly

Early carbohydrate metabolism disorders (ECMDs) and diabetes mellitus (DM) are frequently associated with acromegaly. We aimed to assess the prevalence of ECMDs in patients with acromegaly and to compare the results with those in adults without acromegaly using two population-based epidemiologic surveys. We evaluated 97 patients with acromegaly in several phases of their disease (mean age, 56 years and estimated duration of acromegaly, 12.5 years). An oral glucose tolerance test was done in those not yet diagnosed with DM to reveal asymptomatic DM or ECMDs (impaired glucose tolerance+impaired fasting glucose). Comparisons were made between patients with acromegaly and participants from the general adult population (n=435) and an adult population with multiple type 2 diabetes risk factors (n=314), matched for gender, age and BMI. DM was diagnosed in 51 patients with acromegaly (52.5%) and 14.3% of the general population (P<0.001). The prevalence of ECMDs was also higher in patients with acromegaly than in the general population and in the high-risk group; only 22% of patients with acromegaly were normoglycaemic. The prevalence of newly diagnosed ECMDs or DM was 1.3-1.5 times higher in patients with acromegaly compared with the high-risk group. Patients with acromegaly having ECMDs or DM were older, more obese and had longer disease duration and higher IGF1 levels (Z-score). Logistic regression showed that the severity of glucose derangement was predicted by age, BMI and IGF1 levels. In patients with acromegaly, the prevalence of DM and ECMDs considerably exceeds that of the general population and of a high-risk group, and development of DM depends on age, BMI and IGF1 levels

The role of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: from clinical research to real practice

In type 2 diabetes mellitus (T2DM), the development and progression of cardiovascular diseases occurs, which allows it to be considered as a cardiorenal metabolic syndrome. This should be taken into account when choosing hypoglycemic drugs. Patients with T2DM receiving insulin therapy often have a long history of diabetes, cardiovascular disease, chronic kidney disease, obesity, and need to be prescribed high doses of insulin and/or complex insulin therapy regimens to maintain glycemic control, which does not always lead to the achievement of target levels of glycemia and glycated hemoglobin (HbA1c). Adding to any insulin therapy regimen drugs from the class of sodium-glucose cotransporter type 2 inhibitors (SGLT-2), which have proven their cardio- and renoprotective properties, seems to be a rational combination in patients with T2DM and may have a number of advantages. The article presents 4 clinical examples of dapagliflozin administration, a drug from the SGLT2 class, to patients who are on insulin therapy, having T2DM with a  long history (10–26 years), as well as cardiovascular diseases, chronic kidney disease, and obesity. Dapagliflozin administration allowed to improve glycemic control, to stabilize the insulin dose, as well as reduce body weight without increasing the frequency of serious episodes of hypoglycemia in patients who initially received large doses of insulin. In the long term, we can expect reduction of the progression of cardiovascular risks and the risks of hospitalization due to existing complications of the disease

IDENTIFICATION OF RISK GROUPS FOR TYPE 2 DIABETES MELLITUS BASED ON FINDRISС QUESTIONNAIRE

Background: Prevalence of type 2 diabetes mellitus (T2DM) has reached an epidemic level worldwide and continues to increase steadily.Aim: To assess appropriateness of FINDRISC questionnaire to identify groups with high risk of T2DM in the population of theMoscowregion.Materials and methods: Four hundred and four subjects aged above 18 years in the Lukhovitsy district of theMoscowregion were screened for disturbances of carbohydrate metabolism. All participants filled in the questionnaire of the Finnish Diabetes Association, FINDRISC (the Finnish Diabetes Risk Score). An oral glucose tolerance test was performed in all subjects. Results: Prevalence of carbohydrate metabolism disorders in the study sample was 36.1%. Among them, newly diagnosed T2DM was found in 6.1%, impaired glucose tolerance, in 14.4%, impaired fasting glycaemia, in 18.5%, both impaired glucose tolerance and fasting glycaemia, in 5.7%. Detection of T2DM and early disorders of carbohydrate metabolism was higher in subjects with higher FINDRISC scores. The screening model that includes diagnostic assessment of subjects with a score of≥12 of this questionnaire has adequate sensitivity and specificity to detect T2DM. This model allows for reduction of the necessary sample to 37.5%. Prevalence of cardiovascular risk factors is higher in the subjects with a high FINDRISC score, compared to those with the minimal score.Conclusion: Active implementation of FINDRISC questionnaire among the population of theMoscowregion would allow for timely detection of those with T2DM risk for further screening for disorders of carbohydrate metabolism and introduction of activities to prevent T2DM

EFFECT OF METFORMIN AND PYOGLITAZON ON THE RISK FACTORS OF CARDIOVASCULAR PATHOLOGY DIAGNOSED DURING SCREENING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

Under assessment there was metformin and pyoglitazon effect on the risk factors of cardiovascular disease. During treatment of patients with screening-diagnosed type 2 diabetes mellitus, the following changes were noted: decreasing the levels of glycated hemoglobin, Willebrand factor and C-reactive protein, and increasing the level of HDL cholesterol. It was shown that 6-month-long therapy with metformin and pyoglItazon allowed significant improving glycemia control and influencing markers of cardiovascular risk in these patients

Questionnaire-assessed risk of sleep apnea in inpatients with various endocrine disorders

Background: Sleep breathing disorders can be an additional risk factor for the development of cardiovascular disorders in patients with endocrine disorders.Aim: To assess the sleep apnea risk in patients with various endocrine disorders undergoing inpatient treatment.Materials and methods: The sleep apnea risk and the severity of daytime sleepiness were evaluated in 282 inpatients with endocrine disorders based on the following questionnaires: the Epworth Sleepiness Scale (ESS), the sleep apnea screening questionnaire (SAS), and the Berlin sleep apnea risk questionnaire (BQ). To identify the real prevalence of sleep respiratory disorders in endocrine patients we performed cardio-respiratory monitoring with Watch-PAT200 (“Itamar Medical”, Israel) device in 81 patients.Results: A high sleep apnea risk according to the BQ was detected in 59.9% (160/267) of the patients, according to the SAS in 53.53% (144/269), excessive daytime sleepiness (≥ 11 points) was found in 21.66% (60/277) of the patients with the ESS. Among the patients undergoing cardiorespiratory monitoring, sleep apnea was detected in 84% (68/81), including severe apnea in 38.2% (26/68). The highest sleep apnea risk by BQ and SAS was observed in the patients with type 2 diabetes, acromegaly and hypercortisolism. Excessive daytime sleepiness by the ESS was most noticeable in those with hypercortisolism and thyrotoxicosis.Conclusion: The high risk of sleep apnea in the inpatients with type 2 diabetes mellitus, acromegaly, hypercorticism, and hypothyroidism makes it necessary to include its active screening into the algorithm of their inpatient assessment to rule out any sleep breathing disorder

THE EPIDEMIOLOGICAL SITUATION ON DIABETES MELLITUS IN THE MOSCOW REGION IN THE YEARS 2004-2013

Background: It is extremely important to have information about the main epidemiological indicators characterizing the situation on diabetes mellitus (DM) in Moscow Region. Aim: To assess the dynamics of the main epidemiological indicators of type 1 DM (T1DM) and type 2 DM (T2DM) for the 10-year period (2004-2013). Materials and methods: The study was performed based on the analysis of data of the Moscow Region DM Register, which contained information about 202 909 patients with DM. The indicators are presented per 100 000 of the population. Results: The T1DM prevalence increased from 132.09 to 166.6 per 100 000 within a decade fixed, and that of DM2 – from  2121.9  to 3263.12. The T2DM incidence increased from 193.22 to 224.4. T1DM mortality decreased from 0.9 to 0.6 per 100 000, and in patients with DM2 – from 68.3 to 61.4. The average life expectancy in adult patients with T1DM increased by 1.3 years, in patients with T2DM – by 1.7 years. Conclusion: It was found that the registered prevalence of both T2DM (35%) and T1DM (by 20.5%) increased within the 10-year period. Increase of T2DM incidence was noted in individuals under 40 years of age, and the average peak of T1DM morbidity shifted from the age group of 10-14 years to the 7-9-year group. Cardiovascular diseases are still the prevailing cause of death in T2DM patients (60%). In T1DM patients, the main cause of death was chronic renal failure if onset of the disease occurred in patients under 25, and macrovascular complications – if the first disease manifestation was noted in patients above 25

Assessment of muscle and fat mass in type 2 diabetes mellitus patients by dual-energy X-ray absorptiometry

Background: Obesity is an important health problem, as its prevalence has reached an epidemic level and continues to increase steadily resulting in higher risk of cardiovascular diseases and metabolic disorders. Currently, new methods and criteria are being developed to assess fat and muscle mass, as well as criteria for diagnosing obesity and sarcopenia.Aim: To assess the quantitative composition of muscle and adipose tissue in type 2 diabetes mellitus patients based on the dual-energy X-ray absorptiometry for the diagnosis of obesity and sarcopenia.Materials and methods: We examined 42 type 2 diabetic in-patients admitted to the Department of Therapeutic Endocrinology. Dual-energy X-ray absorptiometry was performed in all patients with subsequent assessment of the composition of muscle and fat tissue.Results: If assessed by the body mass index, all patients had an excess body weight: median, 32.25 [29.75; 35.70]; in men, 31.3 [28.19; 34.63], in women, 32.29 [30.26; 36.54]. 26.2% of the patients (11/42) were overweight, but not obese. Female patients had more severe obesity than male (in total, 33.3% (10/30) of women had 2nd and 3rd degree of obesity, while men 16.7% (2/12)). The assessment by the fat mass index (FMI) showed that 2.4% (1/42) of the patients were normal-weight. Median FMI was 11.91 [10.40; 13.78] (in men, 8.86 [7.46; 12.1], in women, 12.35 [11.55; 15.47]). Overweight was found in 52.4% (22/42) of the patients; in total, 2nd and 3rd degree of obesity was observed in 25% (3/12) of the men and only in 6.6% (2/30) of the women. Median Appendicular Lean Mass Index (ALMI) in the total group was 7.99 [7.32; 9.05], being expectedly higher than in women: 9.19 [8.42; 9.45] and 7.58 [7.24; 8.49], respectively. Median T-score ALMI was 2.32 [1.73; 3.08], Z-score ALMI 2.15 [1.47; 3.54]. In general, there was a decrease in the appendicular muscle mass with age. There was an inverse correlation between the age and T-score ALMI (r = -0.319, р = 0.020), as well as between the age and Z-score ALMI (r = -0.634, p = 0.000). According to the results of T-score ALMI and Z-score ALMI, there were no patients with sarcopenia. However, the calculation of the T- and Z-criteria, corrected for fat mass, has led to a significant decrease of the medians of these parameters and allowed to identify a group of patients meeting the criteria of sarcopenia (97.6%, 41/42).Conclusion: Based on ALMI, T-ALMI, and Z-ALMI, there were no patients with sarcopenia. After these criteria were corrected for fat mass, the number of such patients increased to 97.6% (41/42) and 85.7% (36/42), respectively. The potential use of the adjusted T-ALMI (FMI) and Z-ALMI (FMI) as criteria for sarcopenia and muscle mass reduction compared to the age-related normal values, as well as the classification of obesity by FMI should be studied in large epidemiological studies in different populations

The prevalence of type 2 diabetes and glucose intolerance in the adult population of the Moscow region

Currently in Russia, as well as throughout the world, has been steadily increasing prevalence of type 2 diabetes and early disorders of carbohydrate metabolism - impaired glucose tolerance and impaired fasting glucose. It is shown that in the first year after diagnosis "prediabetes" in 5-10% of patients becomes type 2 diabetes, in five years - at 20-35%. If impaired glucose tolerance combined with impaired fasting glucose, the type 2 diabetes within 5 years develops in 38-65%. The true prevalence of overt type 2 diabetes several times higher than registered, from time to onset of the disease before its detection can reach 7-12 years. Up to 50% of patients with type 2 diabetes at diagnosis already have those or other complications. In this case, early detection of type 2 diabetes and early disorders of carbohydrate metabolism contributes to the timely initiation of treatment and prevention of complications of diabetes, can lead to disability of the patient. The aim of this study was to determine the results of oral glucose tolerance test the prevalence of type 2 diabetes and early disorders of carbohydrate metabolism among a select group of the adult population of the Moscow region

Incidence of sleep apnea in patients with various types of glycemic disturbances

Aims. To assess the risk for sleep apnea in patients with various types of glycemic disorders by means of Epworth Sleepiness Scale andSleep Apnea Screening Questionnaire. Materials and Methods. We examined 744 residents of Mozhaisk Region, that were considered to have high risk for development of type2 diabetes mellitus (T2DM), as estimated by FINDRISK Questionnaire. Patients, who scored 12+ were cleared for participation in this study. Combined score from Epworth Sleepiness Scale and Sleep Apnea Screening Questionnaire was applied for diagnosis of sleep apnea, supplemented with specific questions about snoring and episodes of apnea. Glycemic disorders were diagnosed with standard glucose tolerance test. Results. 42.7% of examined patients (n=318) were diagnosed with various types of glucose disorders. Prevalence of abdominal obe- sity (according to waist circumference measurement) comprised 59.3% in male patients and 54.1% in females. We observed positive correlation between body mass index (BMI) and snoring ? 0.3 (p=0.0001), BMI and apnea ? 0.2 (p=0.0001), BMI and daytime sleepiness ? 0.1 (p=0.007); we also observed direct correlation between age and snoring ? 0.2 (p=0.0001), as well as age and sleep apnea ? 0.1 (p=0.028). Risk for sleep apnea was found to be 4.7 times higher in patients with arterial hypertension. After adjustment71Диагностика, контроль и лечениеСахарный диабет. 2013;(1):71?77Сахар ный диабетfor age risk of apnea remained 2.8 times higher in patients with T2DM, 1.9 times higher in subjects with impaired glucose tolerance and1.6 times higher in subjects with impaired fasting glycaemia. Relative risk for snoring in patients with various types of glycemic disorders was 1.1-1.2 against normoglycemic controls. We estimated that all types of glycemic disorders increase risk for apnea 1.2?1.6 times. Conclusion. Glycemic disorders, body weight excess, obesity and arterial hypertension are risk factors for snoring and sleep apnea. Corresponding patient categories should be screened for sleep apnea by questionnaire survey to identify those in need of further complex examination and treatment